SIRION BIOTECH GMBH

Their core work

Sirion Biotech is a private biotechnology SME based in Planegg-Martinsried, Germany's densest life sciences cluster near Munich. They contribute specialized research tools and biotechnology services to large academic consortia tackling complex biological questions. In H2020, their most substantive contribution was to T2DSystems, a systems biomedicine project integrating transcriptomics, DNA methylomics, chromatin state mapping, and metabolomics to identify biomarkers and build mathematical models of type 2 diabetes and pancreatic beta cell dysfunction. They also served as an associated partner in InCeM, an MSCA training network focused on epithelial cell motility, indicating that their tools have broader applications across cell biology research beyond metabolic disease.

What they specialise in

How they've shifted over time

Both H2020 projects started in 2015–2016, so the portfolio spans a single short window rather than a true long-term arc. Within that window, InCeM (MSCA training network) addressed fundamental cell biology — epithelial cell motility and cytoskeletal dynamics — without disease specificity, while T2DSystems represented a pivot toward high-value disease applications, deploying multi-omic tools against a major chronic condition. The absence of early-period keywords for InCeM and the rich keyword cluster around T2DSystems suggests that Sirion's funded research identity is more firmly anchored in disease-focused systems biology than in basic cell biology training networks.

Sirion appears to be moving from broad cell biology tool provision toward disease-specific functional genomics, with metabolic diseases — particularly type 2 diabetes — as the clearest application area in their H2020 record.

How they like to work

Sirion has never led an H2020 project as coordinator; they join established consortia as a specialist contributor or associated partner. Despite only two projects, they accumulated 41 unique partners across 12 countries, which reflects participation in large, multi-institutional networks rather than small focused teams. This pattern is consistent with a technology-providing SME that supplies specific tools or assay services to academic consortia rather than driving the scientific agenda itself.

With 41 unique consortium partners across 12 countries from just two projects, Sirion's network is disproportionately broad for their project count, reflecting their participation in large pan-European research consortia. Their geographic footprint spans at least a dozen EU member states, consistent with the multi-partner structure of RIA and MSCA-ITN consortia.

What sets them apart

Sirion Biotech's location in Planegg-Martinsried places them at the center of one of Europe's most concentrated biotech ecosystems, giving them proximity to Max Planck Institutes, Helmholtz centers, LMU Munich, and major pharmaceutical companies — an environment that shapes both their technology and their consortium access. As a private SME, they bring industrial-grade biotechnology capabilities into academic research consortia, filling a gap that university labs cannot cover. Their combination of cell biology tool expertise and systems-level disease biology makes them a credible bridge between fundamental research and translational applications in metabolic disease.

Highlights from their portfolio

• T2DSystems
  Sirion's only funded project (EUR 454,500) and their most technically complex engagement — a systems biomedicine RIA integrating five omic layers to model type 2 diabetes risk and treatment, positioning them squarely in translational health research.
• InCeM
  Participation in an MSCA Innovative Training Network demonstrates Sirion's investment in early-career researcher training and their credibility as an industry partner in European doctoral networks.